Business Context and Reporting Period
This Form 8-K is filed by Cactus Ventures, Inc. (the "Company"), a Nevada corporation, with a report date of February 24, 2013. The filing addresses the departure of Mr. Jack Talley, who served as Chief Executive Officer and Director of both Cactus Ventures, Inc. and its subsidiary, Actinium Pharmaceuticals, Inc. The resignation became effective on February 28, 2013.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the executive separation agreement:
- Separation Cash Payment: $250,000 total, payable in two equal installments of $125,000 (March 8, 2013, and September 1, 2013).
- Performance Bonus: $60,000 discretionary bonus for the period of August 15, 2012, to December 31, 2012.
- Benefits: Six months of COBRA continuation coverage under the Company's group health plan.
Material Changes
The primary material change is the resignation of the CEO and a Board Director. The Company explicitly states that Mr. Talley's departure was not based on any disagreement with the Company regarding operations, policies, or practices. The Board is currently seeking to fill the vacancy created by his departure.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The only contingency noted is the execution of the Separation and Settlement Agreement, which includes mutual releases subject to limited exceptions.
Investor Verification Checklist
- Verify the appointment of a new Chief Executive Officer and Director to fill the vacancy left by Mr. Talley.
- Confirm the impact of the $310,000 total separation cost ($250,000 cash + $60,000 bonus) on the Company's immediate cash position.
- Review subsequent filings for any changes in the strategic direction of Actinium Pharmaceuticals, Inc. following the leadership change.